E19 A Selective Approach to Safety Data Collection in Specific Late-Stage Pre-Approval or Post-Approval Clinical Trials
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
December 5, 2022
July 29, 2024
1c6ec306-023c-4065-80cd-a01e6993d76b
Related Documents
General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products Guidance for Industry
Guidance DocumentJuly 27, 2022Center for Drug Evaluation and Research
E9(R1) Statistical Principles for Clinical Trials: Addendum: Estimands and Sensitivity Analysis in Clinical Trials: Guidance for Industry
Guidance DocumentMay 11, 2021Center for Drug Evaluation and Research
Determining the Extent of Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations
Guidance DocumentFebruary 19, 2016Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.